Literature DB >> 17549059

Diabetic neuropathy--a review.

Gérard Said1.   

Abstract

Diabetic neuropathy is the most common neuropathy in industrialized countries, and it is associated with a wide range of clinical manifestations. The vast majority of patients with clinical diabetic neuropathy have a distal symmetrical form of the disorder that progresses following a fiber-length-dependent pattern, with sensory and autonomic manifestations predominating. This pattern of neuropathy is associated with a progressive distal axonopathy. Patients experience pain, trophic changes in the feet, and autonomic disturbances. Occasionally, patients with diabetes can develop focal and multifocal neuropathies that include cranial nerve involvement and limb and truncal neuropathies. This neuropathic pattern tends to occur after 50 years of age, and mostly in patients with long-standing diabetes mellitus. Length-dependent diabetic polyneuropathy does not show any trend towards improvement, and either relentlessly progresses or remains relatively stable over a number of years. Conversely, the focal diabetic neuropathies, which are often associated with inflammatory vasculopathy on nerve biopsies, remain self-limited, sometimes after a relapsing course.

Entities:  

Mesh:

Year:  2007        PMID: 17549059     DOI: 10.1038/ncpneuro0504

Source DB:  PubMed          Journal:  Nat Clin Pract Neurol        ISSN: 1745-834X


  172 in total

Review 1.  Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy.

Authors:  Megan Jack; Douglas Wright
Journal:  Transl Res       Date:  2012-01-10       Impact factor: 7.012

2.  Coordination, childhood weight gain and obesity.

Authors:  Scott M Montgomery
Journal:  CMAJ       Date:  2010-06-28       Impact factor: 8.262

3.  Novel systems for in vivo monitoring and microenvironmental investigations of diabetic neuropathy in a murine model.

Authors:  Sharon Amit; Avraham Yaron
Journal:  J Neural Transm (Vienna)       Date:  2012-05-17       Impact factor: 3.575

4.  Photobiomodulation increases cell viability via AKT activation in an in vitro model of diabetes induced by glucose neurotoxicity.

Authors:  Victória Regina da Silva Oliveira; Rosangela Aparecida Santos-Eichler; Camila Squarzoni Dale
Journal:  Lasers Med Sci       Date:  2019-06-20       Impact factor: 3.161

Review 5.  Schwann cells as a therapeutic target for peripheral neuropathies.

Authors:  Helmar C Lehmann; Ahmet Höke
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-12       Impact factor: 4.388

6.  Poly(ADP-ribose) polymerase inhibition as a novel therapeutic approach against intraepidermal nerve fiber loss and neuropathic pain associated with advanced diabetic neuropathy: a commentary on "PARP Inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy".

Authors:  Pal Pacher
Journal:  Free Radic Biol Med       Date:  2008-01-14       Impact factor: 7.376

7.  L-Arginine supplementation prevents allodynia and hyperalgesia in painful diabetic neuropathic rats by normalizing plasma nitric oxide concentration and increasing plasma agmatine concentration.

Authors:  Lusliany J Rondón; M C Farges; N Davin; B Sion; A M Privat; M P Vasson; A Eschalier; C Courteix
Journal:  Eur J Nutr       Date:  2017-07-19       Impact factor: 5.614

Review 8.  Obesity and vulnerability of the CNS.

Authors:  Annadora J Bruce-Keller; Jeffrey N Keller; Christopher D Morrison
Journal:  Biochim Biophys Acta       Date:  2008-10-17

9.  Hyperglycemia alters the schwann cell mitochondrial proteome and decreases coupled respiration in the absence of superoxide production.

Authors:  Liang Zhang; Cuijuan Yu; Francisco E Vasquez; Nadya Galeva; Isaac Onyango; Russell H Swerdlow; Rick T Dobrowsky
Journal:  J Proteome Res       Date:  2010-01       Impact factor: 4.466

10.  Motor unit number estimate as a predictor of motor dysfunction in an animal model of type 1 diabetes.

Authors:  Nizar Souayah; Joseph G Potian; Carmen C Garcia; Natalia Krivitskaya; Christine Boone; Vanessa H Routh; Joseph J McArdle
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-07-14       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.